157 related articles for article (PubMed ID: 33112366)
1. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
3. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
Raphael BA; Shin DB; Suchin KR; Morrissey KA; Vittorio CC; Kim EJ; Gardner JM; Evans KG; Introcaso CE; Samimi SS; Gelfand JM; Rook AH
Arch Dermatol; 2011 Dec; 147(12):1410-5. PubMed ID: 21844430
[TBL] [Abstract][Full Text] [Related]
4. High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.
Richardson SK; Lin JH; Vittorio CC; Kim EJ; Yoon JS; Junkins-Hopkins J; Rook AH
Clin Lymphoma Myeloma; 2006 Nov; 7(3):226-32. PubMed ID: 17229339
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
[TBL] [Abstract][Full Text] [Related]
6. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy.
Wilson LD; Licata AL; Braverman IM; Edelson RL; Heald PW; Feldman AM; Kacinski BM
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):987-95. PubMed ID: 7607973
[TBL] [Abstract][Full Text] [Related]
7. Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphoma.
Elsayad K; Rolf D; Sunderkötter C; Weishaupt C; Müller EC; Nawar T; Stranzenbach R; Livingstone E; Stadler R; Steinbrink K; Moritz RKC; Eich HT
J Dtsch Dermatol Ges; 2022 Mar; 20(3):279-285. PubMed ID: 34984837
[TBL] [Abstract][Full Text] [Related]
8. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
9. Erythrodermic mycosis fungoides and Sézary syndrome treated with extracorporeal photopheresis as part of a multimodality regimen: A single-centre experience.
Atzmony L; Amitay-Laish I; Gurion R; Shahal-Zimra Y; Hodak E
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2382-9. PubMed ID: 26299651
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response.
Vonderheid EC; Bigler RD; Greenberg AS; Neukum SJ; Micaily B
Am J Clin Oncol; 1994 Jun; 17(3):255-63. PubMed ID: 8192114
[TBL] [Abstract][Full Text] [Related]
11. Total Skin Electron Beam Therapy as Part of Multimodal Treatment Strategies for Primary Cutaneous T-Cell Lymphoma.
Elsayad K; Susek KH; Eich HT
Oncol Res Treat; 2017; 40(5):244-252. PubMed ID: 28448985
[TBL] [Abstract][Full Text] [Related]
12. Acute and sub-acute toxicity profile of ultra-hypofractionated low-dose total skin electron beam with two 4 Gy fractions for cutaneous T cell lymphoma.
Rolf D; Elsayad K; Eich HT
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1757-1761. PubMed ID: 33219856
[TBL] [Abstract][Full Text] [Related]
13. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
Stevens SR; Baron ED; Masten S; Cooper KD
Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
[TBL] [Abstract][Full Text] [Related]
14. Sézary syndrome: diagnostic criteria and therapeutic options.
Russell-Jones R; Whittaker S
Semin Cutan Med Surg; 2000 Jun; 19(2):100-8. PubMed ID: 10892711
[TBL] [Abstract][Full Text] [Related]
15. Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome.
Elsayad K; Kroeger K; Greve B; Moustakis C; Assaf C; Stadler R; Lenz G; Weishaupt C; Eich HT
Strahlenther Onkol; 2020 Jan; 196(1):77-84. PubMed ID: 31591658
[TBL] [Abstract][Full Text] [Related]
16. Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: Real-life experience in Argentina.
Baquero Rey JA; Zambrano Franco EA; Andrade Miranda A; Marciano S; Mazzuoccolo LD; Enz PA
J Clin Apher; 2021 Dec; 36(6):815-822. PubMed ID: 34478581
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
[No Abstract] [Full Text] [Related]
18. Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis.
Kamstrup MR; Gniadecki R; Iversen L; Skov L; Petersen PM; Loft A; Specht L
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):138-43. PubMed ID: 25863761
[TBL] [Abstract][Full Text] [Related]
19. A prospective study on the evolution of the T-cell repertoire in patients with Sézary syndrome treated by extracorporeal photopheresis.
Ingen-Housz-Oro S; Bussel A; Flageul B; Michel L; Dubertret L; Kourilsky P; Gachelin G; Bachelez H; Musette P
Blood; 2002 Sep; 100(6):2168-74. PubMed ID: 12200382
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome.
Fritz TM; Kleinhans M; Nestle FO; Burg G; Dummer R
Br J Dermatol; 1999 Jun; 140(6):1144-7. PubMed ID: 10354086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
